Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were

BMJ. 2018 Sep 19:362:k3783. doi: 10.1136/bmj.k3783.
No abstract available

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Diagnosis-Related Groups / economics
  • Diagnosis-Related Groups / statistics & numerical data
  • Humans
  • Myocardial Infarction / diagnosis*
  • Myocardial Infarction / mortality
  • Myocardial Infarction / psychology
  • Myocardial Infarction / therapy
  • Neoplasms / diagnosis*
  • Neoplasms / mortality
  • Neoplasms / psychology
  • Neoplasms / therapy
  • Quality of Life / psychology
  • Recurrence
  • Risk Factors
  • Stroke / diagnosis*
  • Stroke / mortality
  • Stroke / psychology
  • Stroke / therapy
  • Survival Analysis
  • Therapeutics / adverse effects*
  • Therapeutics / economics
  • Therapeutics / statistics & numerical data
  • Treatment Outcome